Hematologic complications of HIV infection are common and challenge
physicians treating patients at all stages of HIV disease [1,2].
Ineffective hematopoiesis from direct suppression by HIV infection
or excessive cytokine secretion [3-5], infiltrative bone marrow
disease of infectious or neoplastic origin, nutritional deficiencies,
and drug effects all impact on hematopoiesis.
The presence of isolated or trilineage cytopenias is frequently
noted in patients infected with HIV. Anemia, granulocytopenia,
and thrombocytopenia occur in 17%, 8%, and 13%, respectively,
of asymptomatic HIV-infected individuals , and these percentages
increase with advancing HIV disease.
Anemia is the most common hematologic abnormality noted in patients
with HIV infection  (see Table 1). It may develop in patients
with persistent lymphadenopathy who are otherwise asymptomatic
but is more prevalent in patients with overt AIDS, occurring in
66% to 85% of those with advanced disease [5,6].
The anemia appears to be due to ineffective erythropoiesis, possibly
as a direct consequence of HIV infection of erythroid precursors
or, more likely, as a result of the inappropriate release of tumor
necrosis factor (TNF), an inhibitor of erythroid maturation in
vitro [7-9]. The anemia is typically classified as an anemia of
chronic disease, characterized by a low reticulocyte count, elevated
ferritin level, but adequate iron stores noted on bone marrow
biopsy. Review of the peripheral blood smear generally reveals
normocytic, normochromic red blood cells (RBCs).
Common Causes--Infiltrative disease of the bone marrow
caused by Mycobacterium avium complex commonly causes isolated
anemia in patients with advanced HIV disease . The most profound
anemias, with hematocrit concentrations in the 15% to 20% range,
occur in patients with mycobacterial disease. Other infiltrative
processes of the bone marrow, such as fungal infections and lymphoma,
may also cause profound anemia but are usually associated with
decrements in the other cell lines. Anemia associated with constitutional
symptoms, such as fever, night sweats, and weight loss, should
be evaluated with a bone marrow biopsy to rule out an infiltrative
bone marrow condition.
Persistent infection with B19 parvovirus has been associated with
intractable anemia in immunosuppressed patients [11,12]. Classically
associated with transient aplastic crises in patients with underlying
hemolytic diseases or erythroblastosis fetalis, parvovirus selectively
infects actively replicating erythroid precursors, resulting in
RBC lysis and erythroid hypoplasia. Clearance of this infection
is mediated by an intact humoral response; thus, immunocompromised
patients may fail to clear the infection [13,14] or maintain an
adequate IgG antibody response .
Diagnosis of B19 parvovirus infection is made by serologic studies
or bone marrow examination. The presence of giant, abnormal pronormoblasts
is typical of parvovirus infection, (Figure 1) and in situ hybridization,
using sequence-specific DNA probes for B19 parvovirus, confirms
Therapy for this disorder includes a course of intravenous or
intramuscular immunoglobulin, packed RBC transfusions (if indicated),
and folate therapy.
Less common causes of anemia include antibody-mediated
hemolysis and nutritional deficiencies. The presence of RBC autoantibodies
is common in patients at all stages of HIV infection. However,
these autoantibodies rarely are associated with clinically significant
Nutritional deficiencies described in patients with HIV infection
include disorders of iron metabolism or iron deficiency and occult
vitamin B12 deficiency. Folate deficiency does not appear to be
more prevalent in this patient population. Iron deficiency with
a microcytic, hypochromic anemia may result from chronic blood
loss secondary to Kaposi's sarcoma or lymphomatous involvement
of the gastrointestinal tract. Thrombocytopenia may lead to chronic
blood loss, resulting in iron deficiency.
Vitamin B12 deficiency secondary to gastrointestinal malabsorption
has been described increasingly in patients with AIDS. Low serum
vitamin B12 levels associated with altered cobalamin transport
proteins or abnormal absorption of vitamin B12 secondary to chronic
diarrhea have been observed [5,18-20]. Occult vitamin B12 deficiency
may worsen the anemia associated with zidovudine(Retrovir) .
Therefore, it is prudent to monitor vitamin B12 levels periodically
in patients with chronic gastrointestinal dysfunction, especially
those receiving zidovudine therapy.
Infection with HIV affects the lymphocyte, neutrophil, and macrophage-monocyte
cell lines. Despite the hypergammaglobulinemia noted in patients
with HIV disease, they exhibit both defective cellular immunity
and dysregulated humoral immunity. The hallmark of HIV infection
is the progressive depletion of CD4+ lymphocytes . This decrement
presumably occurs through direct viral invasion of these cells.
Early in HIV infection, one may see an initial increase in the
CD8+ population before a decline in the number of CD4+ cells is
Infection of macrophages and monocytes and the triggering of an
autoimmune response are two other mechanisms by which lymphocyte
depletion may occur . Normally, activated T-lymphocytes and
monocytes produce cytokines or growth factors necessary for stem-cell
growth and differentiation. Decreased production of these cytokines
may result from HIV invasion of these cells.
As with anemia, neutropenia is a frequent complication of HIV
infection, but it is generally caused by the use of antiretroviral
drugs or drugs used to treat opportunistic infections (see "Hematologic Consequences of HIV Therapy"below).
Neutropenia is noted in 8% of asymptomatic individuals  and
increases in frequency with advancing disease and therapeutic
The most common cause of neutropenia not due to drug therapy appears
to be ineffective granulopoiesis . Antineutrophil antibodies
have been implicated in certain circumstances [4,5,24,25], but
their prevalence and clinical significance are not well understood.
Defects in qualitative functions, such as defective polymorphonuclear
leukocyte chemotaxis, deficient degranulating responses, inhibition
of leukocyte migration, and ineffective killing have all been
reported [26,27], but their clinical importance remains elusive.
Similarly, HIV-infected monocytes exhibit marked reductions in
chemotaxis and phagocytosis in in vitro studies .
The most common platelet abnormality found in HIV-infected patients
is thrombocytopenia, perhaps due to platelet-associated immunoglobulin
. Other causes of HIV-related thrombocytopenia include circulating
immune complexes that precipitate on the platelet surface ,
cross-reactive antibodies to platelet surface glycoproteins ,
and direct retroviral infection of megakaryocytes [30-32].
Most patients with HIV-related immune thrombocytopenia have only
minor submucosal bleeding, characterized by petechiae, ecchymoses,
and occasional epistaxis. Rare patients have gastrointestinal
blood loss. Unlike non-HIV-related immune thrombocytopenia, mild
splenomegaly may occur, especially in patients with generalized
lymphadenopathy. Laboratory findings reveal isolated thrombocytopenia,
generally without concomitant anemia or leukopenia. Examination
of the peripheral blood smear and bone marrow biopsy are nonspecific,
except for decreased circulating platelet forms and increased
numbers of megakaryocytes seen in the bone marrow.
Drug-induced thrombocytopenia should be ruled out in these patients,
as in non-HIV-infected patients presenting with isolated thrombocytopenia.
Medications that have thrombocytopenia as a side effect should
Immediate Restoration of Platelet Count--For autoimmune-mediated
thrombocytopenia, steroid and immunoglobulin therapy can be initiated
for patients needing immediate restoration of the platelet count.
This may include patients who are experiencing bleeding, those
who will be undergoing a splenectomy procedure, or those in whom
the platelet count is dangerously low and the treating physician
wishes to raise the count immediately. The response of patients
with HIV-related immune thrombocytopenia to steroid therapy is
variable, and the risk of further immune suppression is real.
Often, the platelet count falls as the steroid dose is tapered.
Splenectomy has been a successful therapeutic intervention for
patients who fail to respond to steroid therapy and generally
is not associated with greater morbidity or mortality than in
patients with non-HIV-associated immune thrombocytopenia [33,34].
As mentioned, intravenous gammaglobulin (400 mg/kg/d for 4 to
5 days) may be used to raise the platelet count rapidly, although
its effects are transient, lasting 2 to 3 weeks . The probable
mechanism of its effect is blockade of the reticuloendothelial
system. The high cost and transient nature of immunoglobulin therapy
limit its use to situations in which acute bleeding is occurring
or as a preoperative intervention for patients undergoing splenectomy
when rapid elevation of the platelet count is necessary.
Although platelet transfusions generally are not indicated in
patients with thrombocytopenia of immune origin, treatment with
intravenous gammaglobulin before transfusion in emergency situations
may improve platelet elevation.
Nonimmediate Restoration of Platelet Count--For patients
who do not require an immediate increase in platelet count, the
institution of antiretroviral therapy, if the patient is not yet
on such therapy, may be warranted. Normalization and partial responses
of platelet counts have been noted with the institution of zidovudine
Interferon-alfa (Intron A, Roferon-A) also has been shown to be
efficacious in treating patients with HIV-associated immune thrombocytopenia
in several small studies, although it may be more beneficial in
patients with less advanced HIV disease [38-40]. Partial responses
appear to be more common than complete normalization of platelet
counts, and the drug is relatively well-tolerated at doses of
3 million units given subcutaneously three times a week.
Intravenous or intramuscular administration of anti-D immunoglobulin
has been shown to benefit some Rh-positive patients who, preferably,
have not had a splenectomy [41-43]. The presumed mechanism is
Fc-receptor blockade by antibody-coated RBCs substituting for
the antibody-coated platelets. Clinically significant hemolysis
does not appear to complicate this approach .
The nonandrogenizing testosterone danazol (Danocrine), initially
thought to effectively reverse HIV-related thrombocytopenia, has
not proved to be efficacious in large-scale clinical trials. Less
widely accepted interventions include vincristine and plasmapheresis.
Observation--In the spectrum of HIV-infected individuals,
patients with isolated thrombocytopenia associated with HIV infection
are generally the most healthy. Clinical bleeding is minimal in
these patients, responses to therapeutic interventions are variable,
and spontaneous remissions do occur. Thus, a viable alternative
is to simply observe the patient closely and institute no therapies
directed at correcting the thrombocytopenia until necessary.
1. Doweiko JP: Hematologic aspects of HIV infection. AIDS 7:753-757,
2. Perkocha L, Rodgers G: Hematologic aspects of human immunodeficiency
virus infection: Laboratory and clinical considerations. Ann J
Hematol 29:94-105, 1988.
3. Harbol AW, Liesveld JL, Simpson-Haidaris PJ, et al: Mechanisms
of cytopenia in human immunodeficiency virus infection. Blood
Rev 8(4):241-251, 1994.
4. Donahue R, Johnson M, Zon L: Suppression of in vitro hematopoiesis
following human immunodeficiency virus infection. Nature 326:200-203,
5. Scadden D, Zon L, Groopman J: Pathophysiology and management
of HIV-associated hematologic disorders. Blood 74:1455-1463, 1989.
6. Zon L, Groopman J: Hematologic manifestations of the human
immune deficiency virus. Semin Hematol 25:208-218, 1988.
7. Spivak J, Barnes DC, Fuchs E, et al: Serum immunoreactive erthropoietin
in HIV-infected patients. JAMA 261:3104-3107, 1989.
8. Fauci A, Schnittman S, Polii G: Immunopathogenic mechanisms
in human immunodeficiency virus (HIV) infection. Ann Intern Med
9. Zhang Y, Harada A, Bluethmann H, et al: Tumor necrosis factor
(TNF) is a physiologic regulator of hematopoietic cells: Increase
of early hematopoietic progenitor cells in TNF receptor p55-deficient
mice in vivo and potent inhibition of progenitor cell proliferation
by TNF in vitro. Blood 86(8):2930-2937, 1995.
10. Gascom P, Sathe S, Rameshwar P: Impaired erythropoiesis in
the acquired immunodeficiency syndrome with disseminated mycobacterium
avium complex. Am J Med 94:41-48, 1993.
11. Chernak E, Dubin G, Henry D, et al: Infection due to parvovirus
B19 in patients infected with human immunodeficiency virus. Clin
Infect Dis 20(1):170-173, 1995.
12. Gyllensten K, Sonnerborg A, Jorup-Ronstrom C, et al: Parvovirus
B19 infection in HIV-1 infected patients with anemia. Infection
13. Frickhofen N, Abkowitz JL, Safford M, et al: Persistent B19
parvovirus infection in patients infected with HIV type 1: A treatable
cause of anemia in AIDS. Ann Intern Med 113:926-933, 1990.
14. Naides S, Howard EJ, Swack NS, et al: Parvovirus B19 infection
in HIV type 1-infected persons failing or intolerant to zidovudine
therapy. J Infect Dis 168:101-105, 1993.
15. Bremner J, Beard B, Cohen A: Secondary infection with parvovirus
B19 in an HIV-positive patient. AIDS 7:1131-1132, 1993.
16. McGinniss M, Macher A, Rook A, et al: Red cell autoantibodies
in patients with acquired immune deficiency syndrome. Transfusion
17. Toy P, Reid M, Burns M: Positive direct antiglobulin test
associated with hyperglobulinemia in acquired immunodeficiency
syndrome. Am J Hematol 19:145, 1985.
18. Harriman G, Smith P, Horne M: Vitamin B12 malabsorption in
patients with acquired immunodeficiency syndrome. Arch Intern
Med 149:2039-2041, 1989.
19. Ehrenpreis E, Carlson SJ, Boorstein HL, et al: Malabsorption
and deficiency of vitamin B12 in HIV-infected patients with chronic
diarrhea. Dig Dis Sci 39(10):2159-2162, 1994.
20. Paltiel 0, Falutz J, Veilleux M, et al: Clinical correlates
of subnormal vitamin B12 levels in patients infected with the
human immunodeficiency virus. Am J Hematol 49(4):318-322, 1995.
21. Richman D: AZT collaborative working group:The toxicity of
azidothymidine in the treatment of patients with AIDS and AIDS-related
complex. N Engl J Med 317:192-197,1987.
22. Brizzi M, Porcu P, Porteri A, et al: Haematologic abnormalities
in the acquired immunodeficiency syndrome. Haematologica 75:454-463,
23. Israel D, Plaisance K: Neutropenia in patients infected with
human immunodeficiency virus. Clin Pharm 10: 268-279, 1990.
24. Leiderman I, Greenberg M, Adelsberg B, et al: A glycoprotein
inhibitor of in vitro granulopoiesis associated with AIDS. Blood
25. Murphy M, Metcalfe P, Waters A: Incidence and mechanism of
neutropenia and thrombocytopenia in patients with human immunodeficiency
virus infection. Br J Haematol 66:337-340, 1987.
26. Murphy P, Lane C, Fauci A, et al: Impairment of neutrophil
bactericidal capacity in patients with AIDS. J Infect Dis 158:627-630,
27. Valone F, Payan D, Abrams D, et al: Defective polymorphonuclear
leukocyte chemotaxis in homosexual men with persistent lymph node
syndrome. J Infect Dis 150:267-271, 1984.
28. Karpatkin S: Immunologic thrombocytopenic purpura in HIV-seropositive
homosexuals, narcotic addicts and hemophiliacs. Semin Hematol
29. Battaieb A, Fromont P, Louache F, et al: Presence of cross-reactive
antibody between HIV and platelet glycoproteins in HIV-related
immune thrombocytopenic purpura. Blood 80:162-169, 1992.
30. Louache F, Bettaieb A, Henri A, et al: Infection of megakaryocytes
by HIV in seropositive patients with immune thrombocytopenic purpura.
Blood 78:1697-1705, 1991.
31. Zucker-Franklin D, Termin C, Cooper M: Structural changes
in the megakaryocytes of patients infected with HIV-1. Am J Pathol
32. Zucker-Franklin D, Seremetius S, Zheng Z: Internalization
of HIV-type 1 and other retroviruses by megakaryocytes and platelets.
Blood 75:1920-1923, 1990.
33. Oksenhendler E, Bierling P, Chevret S, et al: Splenectomy
is safe and effective in HIV-related immune thrombocytopenia.
Blood 82:29-32, 1993.
34. Schneider P, Abrams D, Rayneret A, et al: Immunodeficiency-associated
thrombocytopenic purpura: Response to splenectomy. Arch Surg 122:1175-1178,
35. Yap PL, Todd AAM, Williams PE, et al: Use of intravenous immunoglobulin
in acquired immune deficiency syndrome. Cancer 68:1440-1450, 1991.
36. Oksenhendler E, Bierling P, and Ferchal F: Zidovudine for
thrombocytopenic purpura related to human immunodeficiency virus
infection. Ann Intern Med 110:365-368, 1989.
37. Swiss Group for Clinical Studies on AIDS: Zidovudine for the
treatment of thrombocytopenia associated with human immunodeficiency
virus. Ann Intern Med 109:718-721, 1988.
38. Stellini R, Rossi G, Paraninfo G: Interferon therapy in intravenous
drug users with HIV-associated idiopathic thrombocytopenic purpura.
Haematologica 77:418-420, 1992.
39. Vianelli N, Cantai L, Gugliotta L: Recombinant alpha interferon
2b in the therapy of HIV-related thrombocytopenia. AIDS 7:823-827,
40. Fabris F, Sgarabotto D, Zanon E, et al: The effect of a single
course of alpha-2B-interferon in patients with HIV-related and
chronic idiopathic immune thrombocytopenia. Autoimmunity 14(3):175-179,
41. Rossi E, Damasio E, Terragna A: HIV-related thrombocytopenia:
A therapeutical update. Haematologica 76:141-149, 1991.
42. Gringeri A, Cattaneo M, Santagostino E, et al: Intramuscular
anti-D immunoglobulins for home treatment of chronic immune thrombocytopenic
purpura. Br J Haematol 80(3):337-340, 1992.
43. Bussel J, Graziano JN, Kimberly RP, et al: Intravenous anti-D
treatment of immune thrombocytopenic purpura: Analysis of efficacy,
toxicity, and mechanism of effect. Blood 77(9):1884-1893, 1991.
44. Groopman J: Zidovudine intolerance. Rev Infec Dis 12(suppl
45. Gill P, Rarick M, Brynes R: Azidothymidine associated with
bone marrow failure in the acquired immunodeficiency syndrome.
Ann Intern Med 107:502-505,1987.
46. Walker R, Parker R, Kovacs J: Anemia and erythropoiesis in
patients with the acquired immunodeficiency syndrome and Kaposi
sarcoma treated with zidovudine. Ann Intern Med 108:372-376, 1988.
47. Hambleton J, Aragon T, Modin G, et al: Outcome for hospitalized
patients with fever and neutropenia who are infected with the
human immunodeficiency virus. Clin Infect Dis 20:363-371, 1995.
48. Roubey RAS: Autoantibodies to phospholipid-binding plasma
proteins: A new view of lupus anticoagulants and other "antiphospholipid"
autoantibodies. Blood 84(9):2854-2867, 1994.
49. Bloom E, Abrams D, Rodgers G: Lupus anticoagulant in the acquired
immunodeficiency syndrome. JAMA 256:491-493, 1986.
50. Leaf A, Laubenstein L, Raphael B: Thrombotic thrombocytopenic
purpura associated with human immunodeficiency virus type 1 infection.
Ann Intern Med 109:194-197, 1988.
51. Nair J, Bellevue R, Bertoni M, et al: Thrombotic thrombocytopenic
purpura in patients with the acquired immunodeficiency syndrome-related
complex. Ann Intern Med 109:209-212, 1988.
52. Thompson C, Damon LE, Ries CA, et al: Thrombotic microangiopathies
in the 1980s: Clinical features, response to treatment, and the
impact of the HIV epidemic. Blood 80:1890-1895, 1992.
53. Candido A, Rossi P, Menichella G, et al: Indicative morphological
myelodysplastic alterations of bone marrow in overt AIDS. Haematologica
54. Goasguen J, Bennett J: Classification and morphologic features
of the myelodysplastic syndromes. Semin Oncol 19:4-13, 1992.
55. Harris C, Biggs JC, Concannon AJ, et al: Peripheral blood
and bone marrow findings in patients with acquired immune deficiency
syndrome. Pathology 22(4):206-211, 1990.
56. Sasadeusz J, Buchanan M, Speed B: Reactive haemophagocytic
syndrome in human immunodeficiency virus infection. J Infect 20(1):65-68,
57. Abrams D, Chinn E, Lewis B: Hematologic manifestations in
homosexual men with Kaposi's sarcoma. Am J Clin Pathol 81:13-18,
58. Castella A, Croxson T, Mildvan D: The bone marrow in AIDS:
A histologic, hematologic, and microbiologic study. Am J Clin
Pathol 84:425-432, 1985.
59. Mehta K, Gascon P, Robboy S: The gelatinous bone marrow (serous
atrophy) in patients with acquired immunodeficiency syndrome.
Evidence of excess sulfated glycosaminoglycan. Arch Pathol Lab
Med 116(5):504-508, 1992.
60. Northfelt D, Mayer A, Kaplan L: The usefulness of diagnostic
bone marrow examination in patients with HIV infection. J Acquir
Immune Defic Syndr 4:659-666, 1991.
61. Groopman J, Feder D: Hematopoietic growth factors in AIDS.
Semin Oncol 19:408-414, 1992.
62. Miles S: The use of hematopoietic growth factors in HIV infection
and related malignancies. Cancer Invest 9:229-238, 1991.
63. Miles S: Hematopoietic growth factors as adjuncts to antiretroviral
therapy. AIDS Res Hum Retroviruses 8:1073-1079, 1992.
64. Groopman J: Management of the hematologic complications of
human immunodeficiency virus infection. Rev Infect Dis 12:931-937,
65. Baldwin C, Gasson J, Quan S: Granulocyte-macrophage colony-stimulating
factor enhances neutrophil function in acquired immunodeficiency
syndrome patients. Proc Natl Acad Sci USA 85:2763-2766, 1988.
66. Groopman J, Mitsuyasu R, DeLeo M: Effect of recombinant human
granulocyte-macrophage colony-stimulating factor on myelopoiesis
in the acquired immunodeficiency syndrome. N Engl J Med 317:593-598,
67. DaCosta N, Hultin M: Effective therapy of human immunodeficiency
virus-associated anemia with recombinant human erythropoietin
despite high endogenous erythropoietin. Am J Hematol 36: 71-72,1991.
68. Henry D, Beall G, Benson C: Recombinant human erythropoietin
in the therapy of anemia associated with HIV infection and zidovudine
therapy: Overview of four clinical trials. Ann Intern Med 117:739-748,